降钙素基因相关肽
偏头痛
医学
降钙素
单克隆抗体
发病机制
单克隆
疾病
生物信息学
抗体
怀孕
重症监护医学
免疫学
内科学
神经肽
受体
遗传学
生物
出处
期刊:Practical Neurology
[BMJ]
日期:2023-02-08
卷期号:23 (3): 200-207
被引量:1
标识
DOI:10.1136/pn-2022-003592
摘要
The introduction of calcitonin gene-related peptide monoclonal antibodies represents a step forward in preventive migraine treatment as the first agents to target the underlying pathogenesis of migraine. In trials they act more quickly, have better long-term adherence and appear to be better tolerated than other treatments. Major disadvantages are their high cost and unknown safety in pregnancy and in cardiovascular disease. To mitigate these concerns, they should be used according to guidance produced by professional bodies, with defined starting and stopping criteria. We do not yet know whether they are more effective than standard care; many patients may still be better treated by other means, in particular addressing lifestyle factors and medication-overuse headache.
科研通智能强力驱动
Strongly Powered by AbleSci AI